RxDoctor Payments Data

Lora Bowens, APRN

Family · Hurricane, WVNPI 1609052364

Payments from drug & device makers

$931in general payments, 2019–2025

Across 41 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • Otsuka America Pharmaceutical, Inc.$245
  • Idorsia Pharmaceuticals US Inc$98
  • Teva Pharmaceuticals USA, Inc.$84
  • Johnson & Johnson$73
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44
  • plus $96 from 3 others

What the payments were for

  • Food & beverage$931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$931 in reported general payments places this provider in the 65th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$12,143
Medicare patients
44
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$198,791
IngrezzaValbenazine Tosylate15$134,115
Invega SustennaPaliperidone Palmitate14$49,616
VraylarCariprazine Hcl28$39,275
Lurasidone Hcl23$9,829
TrintellixVortioxetine Hydrobromide11$5,555
Quetiapine Fumarate192$4,145
Hydroxyzine Hcl154$3,582
Aripiprazole102$3,182
Buspirone Hcl187$2,969
Lamotrigine164$2,060
Clonazepam268$2,017
Vilazodone Hcl16$1,709
Bupropion XlBupropion Hcl142$1,709
Mirtazapine116$1,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$84$198,79113 claims
Johnson & JohnsonInvega Sustenna$73$49,61614 claims
AbbVieVraylar$291$39,27528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,507 family providers in West Virginia.

Other family in Hurricane

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →